New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 | 05.09.24

• Two abstracts win prestigious AHA 2024 Paul Dudley White International Scholar Award

Allschwil, Switzerland – September 5, 2024
Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2024, taking place September 5-8, 2024 in Chicago, Illinois. On March 19, 2024, aprocitentan was approved in the U.S. as TRYVIO™, with availability planned for Q4 2024. On June 27, 2024, the European Commission granted marketing authorization for JERAYGO™ (aprocitentan).

The following oral and poster presentations will be held:

• Blattmann P, et al. “Correlation between plasma CT-proET-1 and renal dysfunction in patients with resistant hypertension. A biomarker analysis of the PRECISION study”.“, poster presentation by Martine Clozel, Poster Session 2, Salon D, 6 Sep, 9:00 – 10:30 am.
• Clozel M, et al. “Is aprocitentan also sympatholytic in patients with resistant hypertension?”, poster presentation by Martine Clozel, Poster Session 2, Salon D, 6 Sep, 9:00 – 10:30 am.
• Schlaich M, et al. “Impact of arterial stiffness on the blood pressure lowering effect of the dual endothelin antagonist aprocitentan in patients with resistant hypertension”, poster presentation by Markus Schlaich, Poster Session 2, salon D, Sep 6, 9:00 – 10:30 am.
• Weber M, et al. “Effectiveness and safety of aprocitentan in patients with resistant hypertension and elevated NT-proBNP”, moderated poster presentation by Michael Weber, session MPS02, Salon D, New Paradigm and Lessons Learned from Hypertension Clinical Trials in 2024, September 6, 9:15 – 9:20 am.
• Iglarz M, et al.Effect of the endothelin receptor antagonist aprocitentan on plasma endothelin, renin, and aldosterone concentrations in patients with resistant hypertension. A biomarker analysis from the PRECISION study.“, oral presentation by Martine Clozel, session 12.A, Antihypertensives, 6 Sep, 17:30 – 17:45 hrs. Winner of the prestigious AHA 2024 Paul Dudley White International Scholar Award.
• Schlaich M, et al.An important effect of aprocitentan on albuminuria in patients with resistant hypertension“, oral presentation by Markus Schlaich, Session 14.A, Novel Interventions to Improve Blood Pressure Control in the Digital Age, September 7, 8:45 – 9:00 am. Winner of the prestigious AHA 2024 Paul Dudley White International Scholar Award.

More information can be found on the congress website.

Notes to the editor

About the AHA 2024 Paul Dudley White International Scholar Award
The award is presented to the lead author of the highest-ranking abstract submitted from each country to the American Heart Association’s 2024 Hypertension Scientific Sessions. This award is named after Dr. Paul Dudley White, a founding member of the American Heart Association and an early leader in preventive cardiology. It reflects Dr. White’s vision for global excellence in cardiovascular science and medicine.

About aprocitentan
Aprocietentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ET_A and ET_B receptors. In May 2022, Idorsia announced positive topline results from the Phase 3 PRECISION study with aprocitentan for the treatment of patients with resistant hypertension. Detailed results were published in The Lancet and presented as a Late-Breaking Science presentation at the American Heart Association (AHA) Scientific Sessions in November 2022. Further details and commentary can be found in the dedicated press release and an investor webcast with Prof. Markus Schlaich, an investigator at PRECISION. On March 19, 2024, aprocitentan was approved as TRYVIO™ in the U.S., with availability planned for Q4 2024. On June 27, 2024, the European Commission granted Marketing Authorization for JERAYGO™ (aprocitentan).

About Idorsia
Idorsia Ltd strives for more – We have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotechnology hub – Idorsia specializes in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative medicines in the pipeline, an experienced team of professionals spanning all disciplines from lab to bedside, and commercial operations in Europe and North America – the ideal constellation to bring innovative medicines to patients.

Idorsia was listed on the SIX Swiss Exchange in June 2017 (ticker symbol: IDIA) and employs more than 750 highly qualified specialists who are committed to achieving our ambitious goals.

For more information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
[email protected]
[email protected]
www.idorsia.com

The above information contains certain “forward-looking statements” concerning the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “is expected”, “will”, “will continue”, “should”, “would be”, “aims to”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the Company’s investment and research and development programs and expected expenditures in connection therewith, descriptions of new products expected to be introduced by the Company and anticipated customer demand for such products and products in the Company’s existing portfolio. Such statements reflect the Company’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected herein.